Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use.
about
Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosisHemostasis and ageing.Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.International normalized ratio testing with point-of-care coagulometer in healthy term neonatesClinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention.Factor IX and thrombosis.The phenomenon known as acquired activated protein C resistance.Hormone replacement therapy and venous thromboembolism.Risk factors for venous and arterial thrombosisNormal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group.The Laterality of Deep Vein Thrombosis in the Pelvic and Lower Extremity Veins.Can venous thromboembolism navigate the prevention of cardiovascular complications?A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.Molecular mechanisms of age-related regulation of genes.New insights into the mechanisms of venous thrombosis.Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease.Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment.Common risk factors for both arterial and venous thrombosis.An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B LeydenBasic mechanisms and pathogenesis of venous thrombosis.AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score.The hemostatic system through aging and menopause.Thromboelastographic Evaluation of Coagulation in Patients With Liver Disease.Hypercoagulable state, pathophysiology, classification and epidemiology.When von Willebrand disease comes into age - a matter of change?Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.Overview and assessment of risk factors for pulmonary embolism.Retrospective comparison of thromboelastography results to postmortem evidence of thrombosis in critically ill dogs: 39 cases (2005-2010).Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulation.Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris.Hypercoagulable state evaluated by thromboelastography in patients with idiopathic membranous nephropathy.Sex differences in thrombosis.Factor IX and deep vein thrombosis.Hemostatic alterations in patients with acute, unilateral vestibular paresis.A no-reflow prediction model in patients with ST-elevation acute myocardial infarction and primary drug-eluting stenting.Genetic and acquired thrombotic factors in chronic hepatitis C.Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation.Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study.Associations of protein C and protein S with serum lipid concentrations.
P2860
Q28346584-1C5B4996-6145-4B1D-A789-4614EDDF83D3Q33378967-DE96FDF4-24AC-477A-BD96-1218FCAEB29AQ33683302-AEB80ACF-EE8F-4FBF-B4C8-1A0ADE94E6EBQ33929079-AFE76EB3-9D3E-49FB-AA2F-D82127A44CECQ34032366-8DBBDE38-142E-4A8E-B7BB-00E770A27E48Q34104373-C61C3508-4E80-4CB0-9631-ED6A7FE71245Q34530144-5B224315-7BB3-4CF6-9F19-24C75AE61A04Q34575172-B52CB4E5-A30F-433C-BE41-020A092E8726Q34988616-A789E605-C688-487C-8B85-B512608A8AAEQ35082528-9508AC23-578F-4705-BAD8-88E48DD7A05AQ35779950-C4F6D6BA-6F5F-4548-B42D-144C915E0242Q35783633-5A43E568-24CD-4831-93C0-78CFEF1BC801Q35804461-CB100800-745E-458F-A430-0E9DB571CDDBQ36013744-DAEFF9AC-6C49-4265-8036-08A7CE0D1BADQ36068279-B3CA5AEE-E225-4AD6-900B-DBBE76330FA0Q36369902-F88F20F1-B82C-4498-A659-0593994ABCC4Q36555722-309ADA15-E82B-4DBC-BAFC-1A1E2D3E5678Q37084853-9D13C5B7-9A9C-4375-A6C2-C004F09F4CA9Q37172394-86D7C6E6-64BD-4BBA-BC53-6B9D7BAA3B0FQ37388336-255E60D4-6C83-41A6-A295-2C58B1843129Q37496271-33FB237E-9856-496C-8A44-D3FD439C3B8AQ37610388-98DB6D63-6AE0-41DE-8049-2B22AFE4B8BDQ37682987-5566456F-045D-4E27-9C1E-A91E2DF54ECAQ37809540-CC509C65-FBDB-4FEB-A729-4CCF602E3852Q37854842-A59D0471-63F7-4D14-BD38-9D38D4C419F3Q37900368-D6751FCE-8C47-454D-BE24-560A4FF02CFCQ38095148-40A3D0A6-E328-42D5-B113-5993059B3E82Q40125387-69CD9166-2ADD-4638-8166-BFC9331A56F3Q40454871-737C37DD-EE9B-45EE-919A-D1CD5AD1FFA4Q40628124-D39A906A-0D3F-48B8-B66B-2293F82406ACQ40760716-CC96D495-1442-4E68-A817-B348E2CA97D3Q42807454-EF6F71AE-9337-4109-8FB0-5942D5DC6A34Q43137283-7EA0A31E-9B10-4B9C-8E61-625A2A1A71B3Q43562965-6ED02257-97A4-4EAB-BD66-12FC96DA7525Q44127712-06C6989C-68BB-4C4D-9D4A-AE73B9EA7895Q44823742-61CD3535-3395-453C-AC5A-D0AB9769BD84Q45154419-69CEA4A9-BFFD-450F-9458-BC7B226C8935Q45173121-91990D14-048A-4AE5-BEBB-80AAEB4373D7Q46678880-21859929-8D08-4A72-8281-DC31EC724780Q47720534-646C6789-E624-4133-A533-0D751C1A4F96
P2860
Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@en
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@nl
type
label
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@en
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@nl
prefLabel
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@en
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@nl
P2093
P1476
Epidemiology of coagulation fa ...... s by age, sex and hormone use.
@en
P2093
Morrison CE
Philippou H
Tunstall-Pedoe H
Woodward M
P304
P356
10.1046/J.1365-2141.1997.1222936.X
P407
P577
1997-06-01T00:00:00Z